Additional Patients With Brugada Syndrome And Associated Shorter-Than- Normal QT Syndrome

Medical Care Center, Elze, Germany

*Corresponding Author: Prof.Dr.med. Stefan Peters, Medical Care Center , Königsberger Str. 1, 31008 Elze, Phone: 49 5068 9337022, EMail: [email protected]

Received Date: July 06, 2026
Published Date: July 29, 2026

Citation: Peters S. (2026). Additional Patients With Brugada Syndrome And Associated Shorter-Than- Normal QT Syndrome. Mathews J Case Rep. 11(3):231.

Citation: Peters S. (2026).

ABSTRACT

Introduction: Only a few patients with Brugada syndrome and associated shorter-than-normal QT syndrome have been described by Charles Antzelevitch 2007. The association is reported in a few gene mutations such as SCN5A and CACNA1C, CACNB2b and CACNA2D1. Antzelevitch reported on three patients with typical ECG signs of Brugada syndrome, in one patient provoked by ajmaline. All patients had aborted sudden cardiac death.

Method: Additionally, we reported on three more patients, all provoked by ajmaline, with the same phenomenon with typical ECG signs of Brugada syndrome and shorter-than-normal QT syndrome with a QTc interval of 340 to 360 msec. In a young patient with syncope SCN5A mutation was found. In another case with aborted sudden cardiac death so far no mutation could be found. The third patient was withdrawn from blood samples as he migrated to the isle of fuerteventura.

Results: The risk of sudden cardiac death in Brugada syndrome is about 1 %, the risk of sudden cardiac death in short QT syndrome 0.8-1%. The risk of sudden cardiac death in Brugada syndrome and shorter than normal QT overlap syndrome is 66% due to a very low number (n=4/6) of patients.

Conclusions: The combination of Brugada syndrome and shorter than normal QT interval bears to extremely increased risk of sudden cardiac death due to a very low number of patients.